Citadel Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.88M | Buy |
28,300
+5,400
| +24% | +$1M | ﹤0.01% | 4375 |
|
|
2025
Q4 | $4.57M | Sell |
22,900
-12,800
| -36% | -$2.32M | ﹤0.01% | 4423 |
|
|
2025
Q3 | $5.59M | Sell |
35,700
-7,600
| -18% | -$1.21M | ﹤0.01% | 4166 |
|
|
2025
Q2 | $6.57M | Buy |
43,300
+9,000
| +26% | +$1.2M | ﹤0.01% | 3660 |
|
|
2025
Q1 | $5.16M | Sell |
34,300
-10,700
| -24% | -$1.79M | ﹤0.01% | 3815 |
|
|
2024
Q4 | $8.31M | Sell |
45,000
-11,900
| -21% | -$2.29M | ﹤0.01% | 3216 |
|
|
2024
Q3 | $11.2M | Sell |
56,900
-26,100
| -31% | -$5.42M | ﹤0.01% | 2731 |
|
|
2024
Q2 | $17.1M | Buy |
83,000
+39,400
| +90% | +$8.93M | ﹤0.01% | 2154 |
|
|
2024
Q1 | $11.8M | Sell |
43,600
-5,000
| -10% | -$1.19M | ﹤0.01% | 2720 |
|
|
2023
Q4 | $11.5M | Sell |
48,600
-8,300
| -15% | -$1.63M | ﹤0.01% | 2659 |
|
|
2023
Q3 | $11.2M | Buy |
56,900
+48,600
| +586% | +$9.98M | ﹤0.01% | 2551 |
|
|
2023
Q2 | $1.75M | Sell |
8,300
-11,200
| -57% | -$2.23M | ﹤0.01% | 5395 |
|
|
2023
Q1 | $3.94M | Buy |
19,500
+7,100
| +57% | +$1.61M | ﹤0.01% | 4190 |
|
|
2022
Q4 | $2.7M | Sell |
12,400
-36,000
| -74% | -$7.86M | ﹤0.01% | 4925 |
|
|
2022
Q3 | $9.53M | Buy |
48,400
+18,300
| +61% | +$3.95M | ﹤0.01% | 2844 |
|
|
2022
Q2 | $6.44M | Sell |
30,100
-3,400
| -10% | -$831K | ﹤0.01% | 3350 |
|
|
2022
Q1 | $9.51M | Sell |
33,500
-400
| -1% | -$123K | ﹤0.01% | 3026 |
|
|
2021
Q4 | $12.8M | Sell |
33,900
-10,500
| -24% | -$4.08M | ﹤0.01% | 2663 |
|
|
2021
Q3 | $18.3M | Buy |
44,400
+21,800
| +96% | +$9.05M | ﹤0.01% | 2134 |
|
|
2021
Q2 | $8.36M | Hold |
22,600
| – | – | ﹤0.01% | 3400 |
|
|
2021
Q1 | $6.55M | Buy |
22,600
+13,700
| +154% | +$3.81M | ﹤0.01% | 3716 |
|
|
2020
Q4 | $2.22M | Sell |
8,900
-15,900
| -64% | -$3.79M | ﹤0.01% | 5137 |
|
|
2020
Q3 | $5.62M | Sell |
24,800
-19,400
| -44% | -$4.03M | ﹤0.01% | 2993 |
|
|
2020
Q2 | $7.71M | Buy |
44,200
+22,800
| +107% | +$3.64M | ﹤0.01% | 2535 |
|
|
2020
Q1 | $2.7M | Buy |
21,400
+2,400
| +13% | +$360K | ﹤0.01% | 3641 |
|
|
2019
Q4 | $2.9M | Buy |
19,000
+400
| +2% | +$55.4K | ﹤0.01% | 3827 |
|
|
2019
Q3 | $2.46M | Sell |
18,600
-2,200
| -11% | -$295K | ﹤0.01% | 4147 |
|
|
2019
Q2 | $2.95M | Buy |
20,800
+1,200
| +6% | +$163K | ﹤0.01% | 3880 |
|
|
2019
Q1 | $2.85M | Buy |
19,600
+3,800
| +24% | +$499K | ﹤0.01% | 3851 |
|
|
2018
Q4 | $1.79M | Buy |
15,800
+1,800
| +13% | +$225K | ﹤0.01% | 4321 |
|
|
2018
Q3 | $1.88M | Buy |
14,000
+9,400
| +204% | +$1.16M | ﹤0.01% | 4520 |
|
|
2018
Q2 | $516K | Sell |
4,600
-2,000
| -30% | -$216K | ﹤0.01% | 6312 |
|
|
2018
Q1 | $704K | Buy |
6,600
+1,100
| +20% | +$119K | ﹤0.01% | 5316 |
|
|
2017
Q4 | $602K | Buy |
5,500
+300
| +6% | +$32.6K | ﹤0.01% | 5379 |
|
|
2017
Q3 | $562K | Sell |
5,200
-5,900
| -53% | -$606K | ﹤0.01% | 5152 |
|
|
2017
Q2 | $1.12M | Buy |
11,100
+6,300
| +131% | +$580K | ﹤0.01% | 3919 |
|
|
2017
Q1 | $432K | Buy |
+4,800
| New | +$408K | ﹤0.01% | 5264 |
|
|
2016
Q3 | – | Sell |
-3,400
| Closed | -$280K | – | 7288 |
|
|
2016
Q2 | $280K | Sell |
3,400
-1,800
| -35% | -$148K | ﹤0.01% | 5316 |
|
|
2016
Q1 | $395K | Sell |
5,200
-3,800
| -42% | -$281K | ﹤0.01% | 4736 |
|
|
2015
Q4 | $724K | Buy |
9,000
+4,900
| +120% | +$353K | ﹤0.01% | 3988 |
|
|
2015
Q3 | $260K | Buy |
4,100
+3,000
| +273% | +$215K | ﹤0.01% | 5773 |
|
|
2015
Q2 | $77K | Sell |
1,100
-500
| -31% | -$37K | ﹤0.01% | 7329 |
|
|
2015
Q1 | $127K | Sell |
1,600
-600
| -27% | -$44.3K | ﹤0.01% | 6641 |
|
|
2014
Q4 | $140K | Sell |
2,200
-200
| -8% | -$12.5K | ﹤0.01% | 6347 |
|
|
2014
Q3 | $143K | Sell |
2,400
-8,200
| -77% | -$469K | ﹤0.01% | 6059 |
|
|
2014
Q2 | $567K | Buy |
10,600
+1,000
| +10% | +$54.9K | ﹤0.01% | 4227 |
|
|
2014
Q1 | $579K | Buy |
9,600
+2,500
| +35% | +$146K | ﹤0.01% | 4137 |
|
|
2013
Q4 | $377K | Buy |
7,100
+3,300
| +87% | +$166K | ﹤0.01% | 4349 |
|
|
2013
Q3 | $176K | Sell |
3,800
-900
| -19% | -$41.3K | ﹤0.01% | 4880 |
|
|
2013
Q2 | $193K | Buy |
+4,700
| New | +$201K | ﹤0.01% | 4702 |
|
Other funds holding CRL
VCM
VPM
Citadel Advisors's CRL Position: Q1 2026 in Review
Citadel Advisors increased its Charles River Laboratories (CRL) stake by 190% in Q1 2026, buying an estimated $147M and bringing the position to 1,212,152 shares worth $209M. The position accounts for 0.03% of the portfolio, ranked #440.
Citadel Advisors first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Citadel Advisors held 1,212,152 shares of Charles River Laboratories worth $209M as of Q1 2026.
- Citadel Advisors bought 794,636 Charles River Laboratories shares in Q1 2026, an estimated $147M.
- Charles River Laboratories made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #440 holding.
- Citadel Advisors first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.